CDK4 and osteosarcoma: In this study, bioinformatics analysis was employed to identify potential target molecules in osteosarcoma, revealing its genomic characteristics that suggest potential sensitivity to combination therapy with CDK4/6 inhibitors and PARP inhibitors.